Company / R&D per Share
ENANTA PHARMACEUTICALS INC R&D per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$7.72
FY2025
5-year range
$6.76 / $8.37
FY2021-FY2025
Trend
-1.2%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share has fluctuated over the past 10 years, ranging from $1.00 in FY2016 to $8.37 in FY2023.
Based on SEC 10-K filings.
7.72 in FY2025 with a 5-year CAGR of +9.9%.
Declined from $8.37 to $7.72 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- +4.5%
- 5-Year CAGR
- +9.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share decreased 1.2% year-over-year.
- Peak r&d per share was recorded in FY2023.
- Lowest r&d per share in the period was in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $7.72 | -1.2% |
| FY2024 | $7.81 | -6.7% |
| FY2023 | $8.37 | +23.9% |
| FY2022 | $6.76 | -4.6% |
| FY2021 | $7.08 | +47.1% |
| FY2020 | $4.81 | +62.5% |
| FY2019 | $2.96 | +40.0% |
| FY2018 | $2.12 | +73.7% |
| FY2017 | $1.22 | +21.7% |
| FY2016 | $1.00 | +10.5% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026